Trial Profile
A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eden Biologics
- 06 Jan 2020 Status changed from recruiting to discontinued.
- 12 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Aug 2018.
- 29 Mar 2017 Status changed from not yet recruiting to recruiting, according to a JHL Biotech media release.